Aviptadil
Appearance
Clinical data | |
---|---|
AHFS/Drugs.com | International Drug Names |
ATC code |
|
Identifiers | |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
ChEMBL | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C147H237N43O43S |
Molar mass | 3326.83 g·mol−1 |
3D model (JSmol) | |
| |
| |
(what is this?) (verify) |
Aviptadil (INN) is an analog of vasoactive intestinal polypeptide (VIP) for the treatment of erectile dysfunction.[1] Geneva-based Relief Therapeutics Holdings AG RFLB.S has a patent for RLF-100, a synthetic form of a natural peptide that protects the lung. U.S.-Israeli NeuroRx Inc partnered with Relief to develop the drug in the United States. In June 2020, the U.S. Food and Drug Administration granted fast-track designation to RLF-100 for treatment of respiratory distress in COVID-19.[2]
References
- ^ Keijzers GB (April 2001). "Aviptadil (Senatek)". Current Opinion in Investigational Drugs. 2 (4): 545–9. PMID 11566015.
- ^ "Critically ill COVID-19 patients make quick recovery with treatment RLF-100". New York Post. 2 August 2020. Retrieved 3 August 2020.